Microporous Elastomeric Implant for Drusen Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) and diabetic retinopathy, particularly the dry form, lack effective methods to prevent or reverse the progression of drusen formation and associated vision loss, with existing therapies focusing on slowing progression rather than restoration of vision or complete reversal.
Innovation Solution
Implantable microporous devices made of biocompatible elastomeric materials with optimized pore geometry to attract and concentrate macrophage cells, reducing drusen accumulation, inflammation, and promoting a pro-healing environment, which can be injected into the eye to prevent or reverse AMD and diabetic retinopathy progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated injections of anti-inflammatory drugs or anti-angiogenic therapies are administered, then progression of wet AMD or diabetic retinopathy is slowed, but vision loss cannot be restored and treatment compliance becomes difficult
Solution Approach 1:
The microporous device is implanted in advance to create a sustained drug reservoir that continuously releases therapeutic agents over time, eliminating the need for repeated patient visits and injections. The device proactively maintains therapeutic drug levels in the target tissue without requiring ongoing patient compliance with injection schedules.
Solution Approach 2:
The microporous device acts as an intermediary carrier between the drug and target tissue, providing controlled release kinetics and maintaining consistent drug concentrations. This mediator function ensures reliable disease progression control while removing the burden of repeated patient self-administration or clinic visits.
2Reliability
If laser sealing of blood vessels is performed to treat diabetic retinopathy, then leaking vessels are sealed, but vision restoration is not achieved and repeated treatments are required
Solution Approach 1:
The microporous device provides continuous release of therapeutic agents at the implantation site, maintaining sustained control of vascular leakage and inflammation. This continuous action replaces the need for multiple discrete laser treatment sessions, achieving prolonged therapeutic effect from a single implantation procedure.
Solution Approach 2:
The device changes the temporal parameter of drug delivery from acute, repeated interventions to sustained, continuous release. By controlling the release kinetics and maintaining therapeutic drug levels over extended periods, the device achieves reliable leakage control while reducing the frequency of treatment sessions.
3Object-affected harmful factors
If no treatment is given for dry AMD, then no harmful side effects occur, but drusen accumulation progresses and vision loss increases
Solution Approach 1:
The microporous device is designed to be self-contained and self-regulating, using biocompatible materials and controlled release mechanisms that do not require external control or adjustment. The device autonomously maintains therapeutic drug levels and reduces drusen accumulation without causing harmful side effects, preserving vision through sustained local action.
Solution Approach 2:
The microporous structure of the device enables controlled release of therapeutic agents while allowing tissue integration and minimizing foreign body response. The porosity facilitates sustained drug delivery and interaction with surrounding tissue, achieving effective drusen reduction without the harmful side effects associated with systemic or aggressive local therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microporous devices effectively reduce drusen formation, alleviate inflammation, and restore a healthy balance of growth factors, thereby preventing the progression of both dry and wet forms of AMD and diabetic retinopathy, offering a potential cure or significant slowing of disease progression.
Implementation Method 1
The devices are also capable of preventing progression of diabetic retinopathy... the microporous device... comprises a plurality of interconnected pores throughout the device body and extending to the outer surface... attract and concentrate macrophage cells
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
This disclosure provides a method for reducing or preventing the formation and/or accumulation of drusen in an eye of a mammalian subject in need thereof, the method comprising implanting one or more microporous devices into the eye using a needle having an interior dimeter of 0.2-0.3mm. Each device having a device body (10) and an outer surface (18), wherein the microporous device is formed of a biocompatible elastomeric material and comprises a plurality of interconnected pores (16,20) throughout the device body and extending to the outer surface, and wherein substantially all the interconnected pores in the microporous device are each interconnected to at least 2 other pores, a mean diameter of the pores being between about 5 and about 50 micrometers, and any two adjacent pores are connected by a throat (30), a mean throat diameter being at least 5 micrometers.